EP4724471A1 - Agonistes du récepteur double glp-1/gip, double glp-1/gcg et triple glp-1/gip/gcg - Google Patents

Agonistes du récepteur double glp-1/gip, double glp-1/gcg et triple glp-1/gip/gcg

Info

Publication number
EP4724471A1
EP4724471A1 EP24734138.1A EP24734138A EP4724471A1 EP 4724471 A1 EP4724471 A1 EP 4724471A1 EP 24734138 A EP24734138 A EP 24734138A EP 4724471 A1 EP4724471 A1 EP 4724471A1
Authority
EP
European Patent Office
Prior art keywords
amino
acid
group
polypeptide
aib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24734138.1A
Other languages
German (de)
English (en)
Inventor
Rajamannar Thennati
Vinod Sampatrao BURADE
Muthukumaran Natarajan
Dhiren Rameshchandra JOSHI
Manish Harendraprasad Gandhi
Chandulal Thakarshiibhai JIVANI
Abhishek Tiwari
Krunal Harishbhai SONI
Alpeshbhai Balabhai MARU
Pankaj Vinodrao DIXIT
Bharatbhai Balabhai PATELIYA
Ravishankara Madavati NAGARAJA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of EP4724471A1 publication Critical patent/EP4724471A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des agonistes du récepteur triple GLP-1/GIP/GCG et leur utilisation dans le traitement ou la prévention du diabète sucré de type 2 (T2DM), de l'hyperlipidémie/dyslipidémie, de syndromes métaboliques, de la stéatose hépatique associée à un dysfonctionnement métabolique (MASLD), de la stéatohépatite associée à un dysfonctionnement métabolique (MASH), de troubles neurodégénératifs, de la fibrose, de risques cardiovasculaires et/ou de l'obésité.
EP24734138.1A 2023-06-09 2024-06-07 Agonistes du récepteur double glp-1/gip, double glp-1/gcg et triple glp-1/gip/gcg Pending EP4724471A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202321039646 2023-06-09
PCT/IB2024/055618 WO2024252366A1 (fr) 2023-06-09 2024-06-07 Agonistes du récepteur double glp-1/gip, double glp-1/gcg et triple glp-1/gip/gcg

Publications (1)

Publication Number Publication Date
EP4724471A1 true EP4724471A1 (fr) 2026-04-15

Family

ID=91585443

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24734138.1A Pending EP4724471A1 (fr) 2023-06-09 2024-06-07 Agonistes du récepteur double glp-1/gip, double glp-1/gcg et triple glp-1/gip/gcg
EP24734139.9A Pending EP4724472A2 (fr) 2023-06-09 2024-06-07 Nouveaux agonistes du récepteur double glp-1/gip et glp-1/gcg

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP24734139.9A Pending EP4724472A2 (fr) 2023-06-09 2024-06-07 Nouveaux agonistes du récepteur double glp-1/gip et glp-1/gcg

Country Status (6)

Country Link
EP (2) EP4724471A1 (fr)
KR (1) KR20260022948A (fr)
CN (2) CN121263433A (fr)
AU (1) AU2024284396A1 (fr)
MX (1) MX2025014772A (fr)
WO (2) WO2024252366A1 (fr)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
CN103857408B (zh) * 2011-06-22 2017-04-12 印第安那大学科技研究公司 胰高血糖素/glp‑1受体协同激动剂
MX2013015168A (es) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Co-agonista del receptor de glucagon/glp-1.
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
TWI674270B (zh) 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
AR096440A1 (es) 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
JO3575B1 (ar) 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
AR104932A1 (es) * 2015-06-22 2017-08-23 Lilly Co Eli Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
US10676517B2 (en) 2016-03-10 2020-06-09 Medimmune Limited Glucagon and GLP-1 co-agonists for the treatment of obesity
CA3220650A1 (fr) * 2017-09-25 2019-03-28 Merck Sharp & Dohme Llc Co-agonistes a action prolongee des recepteurs du glucagon et du glp-1
CN115304666B (zh) * 2017-11-24 2025-09-19 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
UA128210C2 (uk) 2018-04-05 2024-05-08 Сан Фармасьютікал Індастріз Лімітед Аналог glp-1
AU2019309798A1 (en) 2018-07-23 2021-02-11 Eli Lilly And Company Method of using a GIP/GLP1 co-agonist for diabetes
TWI735917B (zh) 2018-07-23 2021-08-11 美商美國禮來大藥廠 Gip/glp1共促效劑化合物
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
BR112023003668A2 (pt) 2020-10-17 2023-04-25 Sun Pharmaceutical Ind Ltd Agonistas duplos de glp-1/gip
TW202313974A (zh) * 2021-06-08 2023-04-01 瑞典商阿斯特捷利康公司 用於治療肝病之組合療法
CN115975057B (zh) * 2023-03-16 2023-05-16 杭州信海医药科技有限公司 一种可妥度肽的固相合成方法

Also Published As

Publication number Publication date
AU2024284396A1 (en) 2026-01-08
EP4724472A2 (fr) 2026-04-15
WO2024252366A1 (fr) 2024-12-12
CN121263433A (zh) 2026-01-02
KR20260022948A (ko) 2026-02-20
CN121285571A (zh) 2026-01-06
WO2024252367A2 (fr) 2024-12-12
MX2025014772A (es) 2026-01-07
WO2024252367A3 (fr) 2025-02-13

Similar Documents

Publication Publication Date Title
US12622948B2 (en) GLP-1/GIP dual agonists
US10308699B2 (en) Peptidomimetic macrocycles
JP7250814B2 (ja) 新規ｇｌｐ－１類似体
EP2124974B1 (fr) Analogues de glucagon présentant une solubilité améliorée dans des tampons à ph physiologiques
RU2559320C2 (ru) Новые аналоги глюкагона
EP2718317B1 (fr) Analogues de polypeptides insulinotropes dépendants du glucose, compositions pharmaceutiques et son utilisation
US20120101037A1 (en) Glucose-dependent insulinotropic peptide analogs
CN111491658A (zh) 肠促胰岛素类似物及其用途
EP4482578B1 (fr) Agonistes du récepteur crf2 et leur utilisation en thérapie
US20100021480A1 (en) Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same
AU2024284396A1 (en) Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
EP4638481A1 (fr) Agonistes triples des récepteurs glp1/gip/npy2
EP1891106A2 (fr) Nouveaux composes utilises en tant qu'agonistes de glp-i
WO2024098718A1 (fr) Nouveau composé polypeptidique à action prolongée, composition et utilisation associée
CN115873096A (zh) 一种胰高血糖素糖肽-1和胰高血糖素受体双重激动多肽及其应用
CN116514952B (zh) 一类glp-1类似物及其应用
US20230303640A1 (en) Exendin-4 peptide analogs
HK40095414A (en) Crf2 receptor agonists and their use in therapy
EA053025B1 (ru) Двойные агонисты glp-1/gip

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR